Phase II Trial of FOLFOX in Combination With Cetuximab and Concomitant Radiotherapy in the Treatment of Esophageal Cancer Stage III

NCT00578201 Phase 2 COMPLETED

This phase II trial is studying the effects of oxaliplatin, leucovorin and fluorouracil-when given together with Cetuximab and radiation therapy and radiation therapy to see how they work in treating patients with stage III esophageal cancer.

Details

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	Phase 2
Status	COMPLETED
Enrolment	80
Start date	2007-11
Completion	2011-02

Conditions

• Esophageal Cancer Stage III

Interventions

• radiochemotherapy,combination Cetuximab-FOLFOX

Primary outcomes

• objective response rate (ORR) at 12 weeks with radiochemotherapy (first evaluation), and if applicable, within 2 to 4 weeks following the end of additional treatment with the combination Cetuximab-FOLFOX (second evaluation) — at 12 weeks and within 2 to 4 weeks following the end of additionnal treatment

Countries

France